↓ Skip to main content

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial

Overview of attention for article published in Targeted Oncology, November 2020

About this Attention Score

  • Good Attention Score compared to outputs of the same age (65th percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter
3 X users
patent
1 patent

Readers on

mendeley
15 Mendeley